$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2019 Q1 Form 10-K Financial Statement

#000114420419017462 Filed on April 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $50.80K $124.4K $0.00
YoY Change 429.17% 2491.67%
Cost Of Revenue $14.24K $70.38K $10.00K
YoY Change 493.29% 779.69%
Gross Profit $36.56K $54.03K $0.00
YoY Change 407.79% -1788.28%
Gross Profit Margin 71.97% 43.43%
Selling, General & Admin $282.0K $1.050M $150.0K
YoY Change 40.99% 16.91% -11.76%
% of Gross Profit 771.23% 1944.45%
Research & Development $0.00 $96.62K $90.00K
YoY Change -100.0% -62.85% 350.0%
% of Gross Profit 0.0% 178.84%
Depreciation & Amortization $5.290K $21.14K $10.00K
YoY Change -47.1% 32.13%
% of Gross Profit 14.47% 39.13%
Operating Expenses $287.3K $1.168M $240.0K
YoY Change 35.87% -0.54% 26.32%
Operating Profit -$250.7K -$1.114M -$240.0K
YoY Change 22.76% -5.4%
Interest Expense $454.5K $1.361M -$1.230M
YoY Change 137.6% 260.56%
% of Operating Profit
Other Income/Expense, Net -$546.7K -$12.54M
YoY Change -92.59% 746.65%
Pretax Income -$797.4K -$13.66M -$1.480M
YoY Change -89.49% 413.54% 678.95%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$797.4K -$13.66M -$1.480M
YoY Change -89.49% 413.54% 678.95%
Net Earnings / Revenue -1569.62% -10977.21%
Basic Earnings Per Share
Diluted Earnings Per Share -$123.8K -$1.746B -$10.29K
COMMON SHARES
Basic Shares Outstanding 890.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $419.5K $304.1K $10.00K
YoY Change 319.48% 2119.42% -95.45%
Cash & Equivalents $419.5K $13.70K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $163.00 $9.600K $4.801K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $419.6K $313.7K $18.50K
YoY Change 274.98% 1595.46% -91.66%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $158.2K $163.5K $184.6K
YoY Change -11.16% -11.45% 83.47%
TOTAL ASSETS
Total Short-Term Assets $419.6K $313.7K $18.50K
Total Long-Term Assets $158.2K $163.5K $184.6K
Total Assets $577.9K $477.2K $203.1K
YoY Change 99.26% 134.88% -37.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $342.8K $331.8K $237.6K
YoY Change 49.04% 39.68% 257.86%
Accrued Expenses $69.59K $21.64K $23.14K
YoY Change 131.97% -6.48% 374.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $250.0K
YoY Change -100.0% -100.0% 150.0%
Long-Term Debt Due $0.00 $682.1K $250.0K
YoY Change -100.0% 170.93%
Total Short-Term Liabilities $4.183M $4.472M $2.435M
YoY Change -49.12% 83.63% 436.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.183M $4.472M $2.435M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.183M $4.472M $2.439M
YoY Change -49.18% 83.32% 407.87%
SHAREHOLDERS EQUITY
Retained Earnings -$17.88M -$3.426M
YoY Change 346.88%
Common Stock $14.27M $1.190M
YoY Change 95.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.605M -$3.995M -$2.236M
YoY Change
Total Liabilities & Shareholders Equity $577.9K $477.2K $203.1K
YoY Change 99.26% 134.88% -37.01%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$797.4K -$13.66M -$1.480M
YoY Change -89.49% 413.54% 678.95%
Depreciation, Depletion And Amortization $5.290K $21.14K $10.00K
YoY Change -47.1% 32.13%
Cash From Operating Activities -$273.0K -$1.052M -$120.0K
YoY Change 65.53% 18.28% -36.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 388.4K 1.343M 110.0K
YoY Change 53.2% 97.03% -71.05%
NET CHANGE
Cash From Operating Activities -273.0K -1.052M -120.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 388.4K 1.343M 110.0K
Net Change In Cash 115.4K 290.4K -10.00K
YoY Change 30.25% -239.48% -105.26%
FREE CASH FLOW
Cash From Operating Activities -$273.0K -$1.052M -$120.0K
Capital Expenditures $0.00
Free Cash Flow -$120.0K
YoY Change -36.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash
Cash
304056
CY2017Q4 us-gaap Cash
Cash
13697
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9600
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4801
CY2018Q4 us-gaap Assets Current
AssetsCurrent
313656
CY2017Q4 us-gaap Assets Current
AssetsCurrent
18498
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
163505
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
184649
CY2018Q4 us-gaap Assets
Assets
477161
CY2017Q4 us-gaap Assets
Assets
203147
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
331838
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
237566
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21640
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23140
CY2018Q4 us-gaap Management Fee Payable
ManagementFeePayable
198082
CY2017Q4 us-gaap Management Fee Payable
ManagementFeePayable
352750
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
682056
CY2017Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
251748
CY2018Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0
CY2017Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
125000
CY2018Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2017Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
125000
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
10800
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
10800
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3227382
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1309190
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4471798
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2435194
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2017Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
915
CY2018Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2017Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
3211
CY2018Q4 us-gaap Liabilities
Liabilities
4471798
CY2017Q4 us-gaap Liabilities
Liabilities
2439320
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
902711
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
114800
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
12180985
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1074707
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17081333
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3425680
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-3994637
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2236173
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
477161
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203147
CY2018 us-gaap Revenues
Revenues
124400
CY2017 us-gaap Revenues
Revenues
4800
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
70375
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
8000
CY2018 us-gaap Gross Profit
GrossProfit
54025
CY2017 us-gaap Gross Profit
GrossProfit
-3200
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96621
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
260085
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1050485
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
898526
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21144
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15995
CY2018 us-gaap Operating Expenses
OperatingExpenses
1168250
CY2017 us-gaap Operating Expenses
OperatingExpenses
1174606
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-1114225
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-1177806
CY2018 us-gaap Interest Expense
InterestExpense
1361427
CY2017 us-gaap Interest Expense
InterestExpense
377587
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
11588402
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1103715
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12541428
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1481302
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13655653
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
585933658
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106323582
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
408401
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13655653
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2659108
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1877
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
144160
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-2659108
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1258435
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
322555
CY2018 celz Increase In Principal Balance Due To Penalty Provision
IncreaseInPrincipalBalanceDueToPenaltyProvision
12500
CY2017 celz Increase In Principal Balance Due To Penalty Provision
IncreaseInPrincipalBalanceDueToPenaltyProvision
25000
CY2018 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-11588402
CY2017 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-1103715
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4799
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4801
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
94760
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
171181
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
44133
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18932
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4668
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-27250
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1052270
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-889621
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
90000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000
CY2018 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2017 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8200
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1342629
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
681450
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
290359
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-208171
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13697
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221868
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304056
CY2018 us-gaap Interest Paid Net
InterestPaidNet
6712
CY2017 us-gaap Interest Paid Net
InterestPaidNet
11100
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
0
CY2017 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
5546
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
CY2017 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
100000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
11496312
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
314066
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
408401
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2018 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
405294
CY2017 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
CY2018 celz Prepayment Premium Paid On Convertible Debt
PrepaymentPremiumPaidOnConvertibleDebt
57004
CY2017 celz Prepayment Premium Paid On Convertible Debt
PrepaymentPremiumPaidOnConvertibleDebt
0
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1804927
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
483250
CY2018 us-gaap Stock Issued1
StockIssued1
150000
CY2017 us-gaap Stock Issued1
StockIssued1
0
CY2018 celz Non Cash Financing Activities Debt Conversion Beneficial Conversion Feature
NonCashFinancingActivitiesDebtConversionBeneficialConversionFeature
114000
CY2017 celz Non Cash Financing Activities Debt Conversion Beneficial Conversion Feature
NonCashFinancingActivitiesDebtConversionBeneficialConversionFeature
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
903311370
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115399226
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
902711370
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114799226
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> &#160;-&#160;&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1309190
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
3627422
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentration Risks -</div></div></div><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 </div> <div style="font-family:times new roman,times,serif;;display:inline;">per institution.</div> &#160;<div style="font-family:times new roman,times,serif;;display:inline;"><div style="font-size:10pt;;display:inline;">The Company maintains its cash&#160;balances at one financial institution. As of December 31, 2018, the Company&#8217;s balance exceeded the limit by</div> <div style="font-size:10pt;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">54,056</div>.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
10626629
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
8917399
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3227382
CY2018Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
21144
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
21144
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
21144
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
21144
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
21144
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
57785
CY2018 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
248516
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-691368
CY2018 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-234666
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-212729
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13850
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-904097
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1052992
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
950361
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
26319
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
142800
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1079311
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1093161
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3900000
CY2018Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
4186812
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2671002
CY2018 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
197800000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1475650
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
23426087
CY2017Q4 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.0070
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
68048736
CY2018 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.0120
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
336509121
CY2018 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
0.0011
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
142075119
CY2018Q4 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.0047
CY2018 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equityinstruments Outstanding Vested And Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityinstrumentsOutstandingVestedAndExpectedToVestWeightedAverageExercisePrice
0.0047
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P4Y4M24D
CY2017Q1 celz Class Of Warrant Or Right Warrant Term
ClassOfWarrantOrRightWarrantTerm
P2Y4M6D
CY2017Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
5546
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-157791
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000
CY2017 celz Stock Issued During Period Value New Issues With Convertible Notes Payable
StockIssuedDuringPeriodValueNewIssuesWithConvertibleNotesPayable
22500
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
314066
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
112500
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31660
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P4Y2M19D
CY2018 celz Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y2M19D
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.10
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1000000
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
100000
CY2018 celz Stock Issued During Period To Related Party Value New Issues
StockIssuedDuringPeriodToRelatedPartyValueNewIssues
150000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1004683
CY2018 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
10740629
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1877
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000
CY2016Q1 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
64666667
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.017
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.031
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.289
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.037
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2016Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2000
CY2017Q2 celz Patents Payable
PatentsPayable
100000
CY2017Q2 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
100000
CY2017 celz Deferred Income Tax Liability Percent
DeferredIncomeTaxLiabilityPercent
0.35
CY2018 celz Deferred Income Tax Liability Percent
DeferredIncomeTaxLiabilityPercent
0.21
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
522875
CY2017Q4 celz Management Reimbursement Agreementdescription
ManagementReimbursementAgreementdescription
At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days' prior written notice.
CY2017Q4 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
100000
CY2017Q4 celz Common Stock Discount On Shares Percentage
CommonStockDiscountOnSharesPercentage
0.3
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.30
CY2017Q3 celz Redeemable Convertible Debenture Principal And Interest Percentage
RedeemableConvertibleDebenturePrincipalAndInterestPercentage
1.5
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
47500
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26250105
CY2017Q3 celz Redeemable Convertible Debenture Principal And Interest Percentage
RedeemableConvertibleDebenturePrincipalAndInterestPercentage
1.15
CY2017Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
58000
CY2017Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
30000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1315
CY2017Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
25000
CY2018Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12500000
CY2018Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
44000
CY2018Q1 us-gaap Legal Fees
LegalFees
2000
CY2018Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1
CY2018Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
5280000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
132000
CY2018Q3 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
114000
CY2018 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
44000
CY2018Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 celz Working Capital Deficit
WorkingCapitalDeficit
4158142
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther
402310417
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
15200000
CY2018 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Forfeiture In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitureInPeriodWeightedAverageExercisePrice
0
CY2018 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Anti Dilution Modification In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsAntiDilutionModificationInPeriodWeightedAverageExercisePrice
0.0011
CY2018Q4 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equityinstruments Outstanding Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityinstrumentsOutstandingVestedAndExpectedToVest
142075119
CY2017Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
100000
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
54056
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
500000
CY2016Q4 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
0.1000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y9M25D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
22926087
CY2017 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
0.0046
CY2017 celz Share Based Compensation Arrangement By Share Based Payment Award Non Option Equityinstruments Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityinstrumentsGrantedWeightedAverageRemainingContractualTerm
P4Y5M5D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0
CY2017 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0
CY2017 celz Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001187953
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
37242192
CY2018 dei Trading Symbol
TradingSymbol
CELZ
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
890597662
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-017462-index-headers.html Edgar Link pending
0001144204-19-017462-index.html Edgar Link pending
0001144204-19-017462.txt Edgar Link pending
0001144204-19-017462-xbrl.zip Edgar Link pending
celz-20181231.xml Edgar Link completed
celz-20181231.xsd Edgar Link pending
celz-20181231_cal.xml Edgar Link unprocessable
celz-20181231_def.xml Edgar Link unprocessable
celz-20181231_lab.xml Edgar Link unprocessable
celz-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv516069_10k.htm Edgar Link pending
tv516069_ex10-28.htm Edgar Link pending
tv516069_ex3-1.htm Edgar Link pending
tv516069_ex31-1.htm Edgar Link pending
tv516069_ex31-2.htm Edgar Link pending
tv516069_ex32-1.htm Edgar Link pending
tv516069_ex32-2.htm Edgar Link pending